Ionis Pharmaceuticals (IONS) Cash & Current Investments (2009 - 2026)

Ionis Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $1.9 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 10.54% year-over-year to $1.9 billion; the TTM figure through Mar 2026 stood at $1.9 billion (down 10.54% YoY), while the FY2025 annual figure was $2.7 billion, up 16.53% from the prior year.
• Cash & Current Investments was $1.9 billion for Q1 2026 at Ionis Pharmaceuticals, down from $2.7 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.7 billion in Q4 2025 to a low of $1.9 billion in Q1 2026.
• Historically, Cash & Current Investments has averaged $2.2 billion across 5 years, with a median of $2.2 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments climbed 17.98% in 2023, then fell 12.86% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $2.0 billion in 2022, then grew by 17.33% to $2.3 billion in 2023, then dropped by 1.44% to $2.3 billion in 2024, then advanced by 16.53% to $2.7 billion in 2025, then slipped by 28.32% to $1.9 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.9 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.